



Research article

Synthesis, molecular docking study and anticancer activity of novel 1,3,4-oxadiazole derivatives as potential tubulin inhibitors

Tarek A. Yousef^{a,b}, Abdulrahman G. Alhamzani^a, Mortaga M. Abou-Krishna^{a,c},
G. Kanthimathi^d, M.S. Raghu^e, K. Yogesh Kumar^f, M.K. Prashanth^{g,*},
Byong-Hun Jeon^{h,**}

^a College of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University, Riyadh 11623, Saudi Arabia

^b Department of Toxic and Narcotic Drug, Forensic Medicine, Mansoura Laboratory, Medicolegal Organization, Ministry of Justice, Egypt

^c Department of Chemistry, South Valley University, Qena, 83523, Egypt

^d Department of Chemistry, Ramco Institute of Technology, Rajapalayam, Tamilnadu, 626117, India

^e Department of Chemistry, New Horizon College of Engineering, Bengaluru 560 103, India

^f Department of Chemistry, Faculty of Engineering and Technology, Jain University, Ramanagara, 562 112, India

^g Department of Chemistry, B N M Institute of Technology, Bengaluru 560 070, India

^h Department of Earth Resources and Environmental Engineering, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea



ARTICLE INFO

Keywords:

1,3,4-Oxadiazole
Anticancer
Tubulin inhibitors
Molecular docking

ABSTRACT

The current study reports on the synthesis and anticancer efficacy of novel oxadiazole derivatives (8a-f) as tubulin polymerization inhibitors. NMR, mass, and elemental studies were used to confirm the newly produced compounds. In contrast to the conventional medicine colchicine, compounds 8e and 8f demonstrated stronger sensitivity and improved IC₅₀ values in the range of 3.19–8.21 μM against breast MCF-7, colorectal HCT116, and liver HepG2 cancer cell lines. The target compounds were tested for enzymatic activity against the tubulin enzyme. Compounds 8e and 8f were shown to have the most effective inhibitory action among the new compounds, with IC₅₀ values of 7.95 and 9.81 nM, respectively. As compared to the reference drug, molecular docking investigations of the developed compounds revealed the crucial hydrogen bonding in addition to the hydrophobic interaction at the binding site, assisting in the prediction of the structural requirements for the found anticancer activity. These findings indicate that the 1,3,4-oxadiazole scaffold has the potential for future research into new anticancer medicines.

1. Introduction

Cancer is a category of disorders defined by uncontrolled cell growth with the ability to expand into or invade neighboring tissues in a process known as metastasis, which is the leading cause of mortality from cancer [1]. Cancer is currently considered a severe health issue on a global scale. Without appropriate treatments, the number of cancer-related fatalities among cancer patients is predicted to

* Corresponding author.

** Corresponding author. Department of Earth Resources and Environmental Engineering, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.

E-mail addresses: prashanthmk87@gmail.com (M.K. Prashanth), bhjeon@hanyang.ac.kr (B.-H. Jeon).

<https://doi.org/10.1016/j.heliyon.2023.e13460>

Received 6 November 2022; Received in revised form 25 January 2023; Accepted 31 January 2023

Available online 8 February 2023

2405-8440/© 2023 Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

increase to 13 million in 2030 and 16 million in 2040, respectively [2]. Despite extensive use of personnel and material resources, there is still no safe and effective cancer treatment agent. Because of the overall toxicity associated with the clinical use of conventional cancer chemotherapeutic drugs, the effective treatment of cancer remains a considerable problem despite advances in our understanding of the biochemical mechanisms involved in carcinogenesis [3,4].

Microtubules, a significant component of the cytoskeleton, serve critical functions in a broad range of cellular activities [5]. Tubulin, the primary protein component of microtubules, has been identified as a promising and effective therapeutic target in cancer therapy [6]. It has been contending that microtubules represent the best cancer target that has been discovered thus far in light of the success of this class of medications, and it appears likely that medications of this class will continue to be significant chemotherapeutic agents, even as more selective approaches are developed [7]. The tubulin binding sites for colchicine, vinblastine, and paclitaxel are generally well-defined [8]. Agents that attach to the colchicine or vinca alkaloid binding sites are identified as tubulin assembly inhibitors or microtubule destabilizing agents. In contrast, drugs that bind to the paclitaxel binding site are either tubulin promoters or microtubule stabilizers [9]. Although the impressive anti-proliferative effects of the colchicine binding site inhibitors in recent years [10], no colchicine site tubulin inhibitors have been given clinical approval. Thus, the need for novel colchicine site tubulin inhibitors with potent anticancer action and manageable side effects is essential.

Diverse heterocyclic compounds have become particularly important in the drug development process. Medical chemists are interested in designing novel bioactive chemicals based on molecular recognition. In recent years, heterocyclic rings with nitrogen atoms have become quite important in medicinal chemistry. They are regarded as essential models for the creation of novel therapeutics [11]. Oxadiazoles holds a special place among these privileged moieties because of their function in the creation of anticancer medications [12,13]. Researchers have been interested in 1,3,4-oxadiazole, one of the isomers of oxadiazole, because of its distinct pharmacokinetic characteristics and its increases the drug's lipophilicity. This molecule's characteristic aids in the transmembrane diffusion of the medication to the target location [14]. The utilization of the 1,3,4-oxadiazole scaffold as a core component in a variety of enzyme inhibitors [15] demonstrates the scaffold's adaptability and effectiveness. Over the last few decades, the development of novel oxadiazole-based scaffolds has increased in medicinal chemistry, with the majority of these molecules progressing to the pre-clinical stage or even commercialization. Several oxadiazole derivatives with anticancer properties have been identified, depending on the substituents and locations of heteroatoms. Recently, new topsentin linked 1,3,4-oxadiazoles and indole linked 1,3,4-oxadiazoles demonstrated anticancer potential via tubulin polymerization inhibition [16,17]. Furthermore, another group of 1,3,4-oxadiazole compounds has been shown to have antiproliferative, antimitotic, and microtubule destabilizing activity profiles equivalent to combretastatin, podophyllotoxin, and nocodazole [18]. Fig. 1 shows the structures of a few therapeutically utilized medications that share the 1,3,4-oxadiazole scaffold [19].

A new series of oxadiazole derivatives (8a-f) were developed and synthesized based on these biological implications and in continuation of our interest in the design and development of novel therapeutic medicines [20–26]. The cytotoxic potential of each newly synthesized target molecule was tested against the MCF-7, HepG2, and HCT116 cancer cell lines. Additionally, it was assessed if newly produced chemicals may impede the polymerization of tubulin. Additionally, molecular docking experiments were conducted to clarify its potential tubulin binding manner.

2. Experimental section

2.1. Materials

All of the chemicals purchased were analytical reagent grade and were utilized exactly as received. On a Bruker AM 400 spectrometer using DMSO (d_6) as a solvent, ^1H NMR (400 MHz) spectra were recorded. The mass spectra were recorded using a PerkinElmer PE Sciex API/65 LC-MS apparatus. A PerkinElmer type 240C analyzer was used to examine the elements (C, H, and N). A Koffler device was used to determine the melting point.




Fig. 1. Commercially available drugs sharing oxadiazole scaffold.

2.2. Synthesis

2.2.1. Synthesis of 2-((4-(trifluoromethyl)benzylidene)amino)benzenethiol (3)

At 80 °C in an inert atmosphere of argon, an ethanolic solution of 2-aminobenzenethiol (3 mmol) was added drop by drop into an ethanolic solution of 4-(trifluoromethyl)benzaldehyde (3 mmol). After the reaction was completed, the reaction mixture was refluxed for 6 h, and the solid product was produced. The reaction mixture was allowed to cool to ambient temperature before filtering, and the residue was washed with cold ethanol and dried under a vacuum. Yield: 91%. Anal. calc. for C₁₄H₁₀F₃NS: C, 59.78; H, 3.58; N, 4.98. Found: C, 59.73; H, 3.54; N, 5.03. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 3.56 (s, 1H, –SH), 7.09–7.79 (m, 8H, Ar–H), 8.65 (s, 1H, –CH=N). MS, *m/z*: 282 (M+1).

2.2.2. Synthesis of S-(2-((4-(trifluoromethyl)benzylidene)amino)phenyl) ethanethioate (4)

A mixture of compound 3 (2 mmol), acetic anhydride (2.2 mmol), K₂CO₃ (2.2 mmol), and acetone (10 mL) was refluxed for 2 h. TLC was used to monitor the reaction's development. After the reaction was finished, the mixture was filtered and the filtrate was concentrated. Dichloromethane (15 mL) and water (5 mL) were added to the residue. To get compound 4, the organic phase was dried with sodium sulphate and concentrated. Yield: 91%. Anal. calc. for C₁₆H₁₂F₃NOS: C, 59.43; H, 3.74; N, 4.33. Found: C, 59.41; H, 3.70; N, 4.37. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.28 (s, 3H, –CH₃), 7.08–7.74 (m, 8H, Ar–H), 8.65 (s, 1H, –CH=N). MS, *m/z*: 324 (M+1).

2.2.3. Synthesis of S-(2-((4-(trifluoromethyl)benzyl)amino)phenyl) ethanethioate (5)

To the methanolic solution of compound 4 (2 mmol), sodium borohydride (4 mmol) and *p*-toluenesulfonic acid monohydrate (4 mmol) were added dropwise. Following the addition, the reaction mixture was refluxed for 2 h before being cooled. Upon the quenching of the reaction mixture with saturated NaHCO₃ solution, the product was extracted with EtOAc, dried over anhydrous Na₂SO₄, the solvent was evaporated, and the solvent was then recrystallized from ethanol to produce compound 5. Yield: 78%. Anal. calc. for C₁₆H₁₄F₃NOS: C, 59.07; H, 4.34; N, 4.31. Found: C, 59.04; H, 4.31; N, 4.36. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.26 (s, 3H, –CH₃), 4.38 (s, 2H, –CH₂), 5.61 (s, 1H, –NH), 6.98–7.87 (m, 8H, Ar–H). MS, *m/z*: 326 (M+1).

2.2.4. General procedure for the synthesis of compounds 7a-f

In an ice bath, the compound 5 (1 mmol) in dichloromethane (5 mL) was cooled to 0–5 °C. Triethylamine (1.2 mmol) was added to the reaction mixture under cold conditions and agitated for 30 min before adding various substituted 2-(chloromethyl)-1,3,4-oxadiazoles (6a-f) and stirring at room temperature for 6 h. After the reaction was completed (TLC), the reaction mixture was quenched with saturated NaHCO₃ solution; the product was extracted with EtOAc, dried over anhydrous Na₂SO₄, and the solvent was evaporated and recrystallized from ethanol to produce the matching 7a-f compounds.

2.2.4.1. S-(2-(((5-methyl-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino)phenyl) ethanethioate (7a). Yield: 94%. Anal. calc. for C₂₀H₁₈F₃N₃O₂S: C, 57.00; H, 4.31; N, 9.97. found: C, 56.; H, 4.28; N, 9.98. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.28 (s, 3H, –CH₃), 2.67 (s, 3H, –CH₃), 3.55 (s, 1H, –SH), 4.59 (s, 2H, –CH₂), 5.03 (s, 2H, –CH₂), 7.02–7.76 (m, 8H, Ar–H). MS, *m/z*: 422 (M+1).

2.2.4.2. S-(2-(((5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) phenyl) ethanethioate (7b). Yield: 91%. Anal. calc. for C₂₀H₁₅F₆N₃O₂S: C, 50.53; H, 3.18; N, 8.84. found: C, 50.51; H, 3.16; N, 8.87. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.68 (s, 3H, –CH₃), 3.54 (s, 1H, –SH), 4.56 (s, 2H, –CH₂), 5.05 (s, 2H, –CH₂), 7.03–7.59 (m, 8H, Ar–H). MS, *m/z*: 476 (M+1).

2.2.4.3. S-(2-(((5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) phenyl) ethanethioate (7c). Yield: 89%. Anal. calc. for C₂₅H₁₉F₄N₃O₂S: C, 59.87; H, 3.82; N, 8.38. found: C, 59.85; H, 3.78; N, 8.43. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.66 (s, 3H, –CH₃), 3.57 (s, 1H, –SH), 4.55 (s, 2H, –CH₂), 5.07 (s, 2H, –CH₂), 7.03–7.78 (m, 12H, Ar–H). MS, *m/z*: 502 (M+1).

2.2.4.4. S-(2-(((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) phenyl) ethanethioate (7d). Yield: 92%. Anal. calc. for C₂₅H₁₉ClF₃N₃O₂S: C, 57.97; H, 3.70; N, 8.11. found: C, 57.95; H, 3.67; N, 8.16. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.68 (s, 3H, –CH₃), 3.56 (s, 1H, –SH), 4.54 (s, 2H, –CH₂), 5.06 (s, 2H, –CH₂), 7.01–7.86 (m, 12H, Ar–H). MS, *m/z*: 518 (M+1).

2.2.4.5. S-(2-((4-(trifluoromethyl)benzyl)((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)methyl) amino)phenyl) ethanethioate (7e). Yield: 90%. Anal. calc. for C₂₆H₁₉F₆N₃O₂S: C, 56.62; H, 3.47; N, 7.62. found: C, 56.61; H, 3.43; N, 7.67. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.64 (s, 3H, –CH₃), 3.55 (s, 1H, –SH), 4.52 (s, 2H, –CH₂), 5.08 (s, 2H, –CH₂), 6.98–7.83 (m, 12H, Ar–H). MS, *m/z*: 552 (M+1).

2.2.4.6. S-(2-(((5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) phenyl) ethanethioate (7f). Yield: 87%. Anal. calc. for C₂₅H₁₉F₃N₄O₄S: C, 56.81; H, 3.62; N, 10.60. found: C, 56.78; H, 3.61; N, 10.65. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.67 (s, 3H, –CH₃), 3.56 (s, 1H, –SH), 4.55 (s, 2H, –CH₂), 5.06 (s, 2H, –CH₂), 7.02–7.91 (m, 12H, Ar–H). MS, *m/z*: 529 (M+1).

2.2.5. General procedure for the synthesis of compounds 8a-f

Under inert conditions, 5 mmol of NaOH solution was added dropwise to the ethanolic (10 mL) solution of compound 7a-f (1 mmol). The reaction mixture was allowed to reflux for 2 h before being cooled to room temperature and neutralized with HCl solution.

To get pure corresponding products 8a-f, the product was extracted with dichloromethane, dried over Na₂SO₄, and concentrated in vacuo.

2.2.5.1. 2-(((5-Methyl-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino)benzenethiol (8a). Yield: 93%. Mp.: 216–218 °C. Anal. calc. for C₁₈H₁₆F₃N₃OS: C, 56.98; H, 4.25; N, 11.08. found: C, 56.95; H, 4.22; N, 11.13. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 2.67 (s, 3H, –CH₃), 3.56 (s, 1H, –SH), 4.55 (s, 2H, –CH₂), 5.06 (s, 2H, –CH₂), 7.03 (t, 1H, Ar–H), 7.18 (m, 2H, Ar–H), 7.33 (t, 1H, Ar–H), 7.40 (t, 2H, Ar–H), 7.58 (d, 2H, Ar–H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 20.5, 57.1, 58.2, 114.6, 117.1, 118.5, 124.1, 124.9, 126.4, 129.1, 129.5, 130.3, 142.1, 145.2, 163.2, 164.7. MS, *m/z*: 380 (M+1).

2.2.5.2. 2-(((5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) benzenethiol (8b). Yield: 91%. Mp.: 210–212 °C. Anal. calc. for C₁₈H₁₃F₆N₃OS: C, 49.89; H, 3.02; N, 9.70. found: C, 49.86; H, 3.01; N, 9.74. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 3.56 (s, 1H, –SH), 4.55 (s, 2H, –CH₂), 5.06 (s, 2H, –CH₂), 7.04 (m, 3H, Ar–H), 7.17 (m, 2H, Ar–H), 7.32 (m, 1H, Ar–H), 7.46 (m, 2H, Ar–H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 57.1, 58.2, 114.6, 117.1, 118.5, 121.2, 124.1, 124.9, 126.4, 129.1, 129.5, 130.3, 142.1, 145.2, 163.2, 163.5. MS, *m/z*: 434 (M+1).

2.2.5.3. 2-(((5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) benzenethiol (8c). Yield: 86%. Mp.: 225–227 °C. Anal. calc. for C₂₃H₁₇F₄N₃OS: C, 60.12; H, 3.73; N, 9.15. found: C, 60.09; H, 3.71; N, 9.17. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 3.58 (s, 1H, –SH), 4.56 (s, 2H, –CH₂), 5.08 (s, 2H, –CH₂), 7.05 (t, 2H, Ar–H), 7.16 (m, 3H, Ar–H), 7.39 (m, 3H, Ar–H), 7.69 (t, 2H, Ar–H), 7.79 (m, 2H, Ar–H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 57.1, 58.2, 114.6, 116.2, 117.1, 118.5, 121.7, 124.1, 124.9, 126.4, 129.1, 129.3, 129.5, 130.3, 142.1, 145.2, 162.9, 163.2, 164.5. MS, *m/z*: 460 (M+1).

2.2.5.4. 2-(((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) benzenethiol (8d). Yield: 89%. Mp.: 229–231 °C. Anal. calc. for C₂₃H₁₇ClF₃N₃OS: C, 58.05; H, 3.60; N, 8.83. found: C, 58.01; H, 3.57; N, 8.89. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 3.56 (s, 1H, –SH), 4.54 (s, 2H, –CH₂), 5.05 (s, 2H, –CH₂), 7.02 (t, 2H, Ar–H), 7.15 (m, 3H, Ar–H), 7.29 (m, 3H, Ar–H), 7.73 (t, 2H, Ar–H), 7.86 (m, 2H, Ar–H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 57.1, 58.2, 114.6, 117.1, 118.5, 124.1, 124.5, 124.9, 126.4, 128.6, 129.1, 129.3, 129.5, 130.3, 134.3, 142.1, 145.2, 163.2, 164.5. MS, *m/z*: 476 (M+1).

2.2.5.5. 2-(((4-(trifluoromethyl)benzyl)((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)methyl) amino)benzenethiol (8e). Yield: 86%. Mp.: 237–239 °C. Anal. calc. for C₂₄H₁₇F₆N₃OS: C, 56.58; H, 3.36; N, 8.25. found: C, 56.55; H, 3.32; N, 8.28. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 3.59 (s, 1H, –SH), 4.57 (s, 2H, –CH₂), 5.09 (s, 2H, –CH₂), 7.03 (t, 2H, Ar–H), 7.18 (m, 3H, Ar–H), 7.33 (m, 3H, Ar–H), 7.72 (t, 2H, Ar–H), 7.77 (m, 2H, Ar–H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 57.1, 58.2, 114.6, 117.1, 118.5, 124.1, 124.4, 124.9, 125.6, 126.4, 126.8, 127.5, 129.1, 129.5, 130.3, 131.2, 142.1, 145.2, 163.2, 164.5. MS, *m/z*: 510 (M+1).

2.2.5.6. 2-(((5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino) benzenethiol (8f). Yield: 87%. Mp.: 244–246 °C. Anal. calc. for C₂₃H₁₇F₃N₃O₃S: C, 56.79; H, 3.52; N, 11.52. found: C, 56.76; H, 3.51; N, 11.57. ¹H NMR (100 MHz, DMSO-*d*₆) δ: 3.57 (s, 1H, –SH), 4.54 (s, 2H, –CH₂), 5.08 (s, 2H, –CH₂), 7.06 (t, 2H, Ar–H), 7.21 (m, 3H, Ar–H), 7.35 (m, 3H, Ar–H), 7.71 (t, 2H, Ar–H), 7.89 (m, 2H, Ar–H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ: 57.1, 58.2, 114.6, 117.1, 118.5, 124.1, 124.9, 126.4, 128.7, 129.1, 129.5, 130.3, 130.9, 132.2, 142.1, 145.2, 147.9, 163.2, 164.5. MS, *m/z*: 487 (M+1).

2.3. Cell viability assessment

The percentage of viable cells may be determined spectrophotometrically using the MTT test, which assesses the metabolic activity of the viable cells based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium salt (MTT) to formazan product. MCF-7, HCT116, HepG2 and Vero cell lines were utilized to assess the cytotoxic activity of compounds 8a-f using the MTT assay, which has been previously described [24]. The reference medication used was called colchicine.

2.4. Tubulin polymerization assay

The effect of the synthesized compounds 8a-f on tubulin polymerization was evaluated turbidimetrically using a fluorescence plate reader technique [27].

2.5. Molecular docking studies

Utilizing the UCSF Chimera tool, the newly synthesized potent molecules molecular docking study was carried out. In order to dock with potent molecules, the protein tubulin complex with colchicine (PDB ID: 4O2B) was chosen as the ideal target protein. The target proteins' X-ray crystal structure was retrieved from the Protein Data Bank (PDB). It is done to standardize and streamline the target protein and ligand. The xyz coordinates across the binding site of the enzyme were categorized using a grid. By using the Discovery Studio Visualizer, the docking results were visualized and examined. The features of the synthesized compounds that are similar to those found in drugs were predicted using the online server <http://www.swiss adme.ch>.


3. Results and discussion

3.1. Synthesis

The synthetic pathway used to generate substituted 2-(((1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl)benzyl)amino)benzenethiol derivatives is depicted in [Scheme 1](#). When 2-aminobenzenethiol (1) and 4-(trifluoromethyl)benzaldehyde (2) are condensed using ethanol as a solvent in an inert environment, 2-(((4-(trifluoromethyl)benzylidene)amino)benzenethiol is obtained (3). The presence of the two-singlet signal at 3.56 and 8.65 ppm, corresponding to the thiol and imine groups, respectively, in the ^1H NMR spectrum demonstrated that the synthesized compound 3 was produced via condensation. In the second phase of the process, molecule 3 is acetylated with acetic anhydride to preserve the thiol group, producing *S*-(2-(((4-(trifluoromethyl)benzylidene)amino)phenyl)ethanethioate (4) with a 91% conversion rate. The ^1H NMR spectra of compound 4 show the presence of a thioacetate linkage due to the elimination of the singlet peak at 3.56 ppm and the emergence of a new singlet peak at 2.28 ppm. The imine group in compound 4 is then reduced with a solution of sodium borohydride and *p*-toluenesulfonic acid monohydrate to produce compound 5, which has a secondary amine group in a fair yield. The reduction of imines to secondary amine is demonstrated by the elimination of the imine peak and the formation of new singlet peaks at 4.38 and 5.61 ppm for the methylene and –NH groups, respectively, in the ^1H NMR spectra of compound 5. Later, amidation of compound 5 in dichloromethane with substituted 2-(chloromethyl)-1,3,4-oxadiazoles (6a-f) produced substituted 2-(((1,3,4-oxadiazol-2-yl)methyl)(4-(trifluoromethyl) benzyl)amino)benzenethiol derivatives (7a-f) in excellent yields. The synthesis of compounds 7a-f has been confirmed by the absence of the –NH proton signal at 5.61 ppm in the ^1H NMR spectra of compounds 7a-f compared to compound 5. Deprotection of the acetyl group from compounds 7a-f with sodium hydroxide was followed by acidification with HCl to produce the target compounds 8a-f. The development of the singlet signal at 3.56–3.59 ppm indicates the thiol group's existence in compounds 8a-f. Based on the ^1H NMR, ^{13}C NMR and mass spectra, the structures of the synthesized compounds were inferred ([Table 1](#)). Elemental analysis was used to determine the composition of each molecule. The chemical shift and multiplicity patterns also showed good agreement with the suggested structures. The results of the elemental analysis revealed good agreement between the values that were calculated theoretically and those that were empirically determined. All recently synthesized compounds had a M+1 peak in their mass spectra, which was consistent with their chemical formula.

3.2. Cytotoxic activity

We evaluated the cytotoxicity of the target compounds 8a-f against three human cancer cell lines, including MCF-7 (breast), HCT116 (colorectal), and HepG2 (liver) to examine the anticancer properties of the synthesized compounds. [Table 2](#) presents a summary of the outcomes. The MTT testing findings revealed that synthetic substances had exceptional lethal effects on all of the examined cancer cell types. Compounds 8d, 8e, and 8f in this series show substantial anticancer activity against all examined human cancer cell lines. Particularly, compounds 8e and 8f, with IC_{50} values of 2.18, 7.49, and 5.36 μM and 2.18, 7.49, and 5.36 μM , respectively, had more activity than the reference drug against the MCF-7, HCT116, and HepG2 cell lines. Specifically, compound 8e, which has IC_{50} values against the HCT116, HepG2, and MCF-7 cell lines of 3.19, 5.43, and 7.89 μM , respectively, which are around 2.33, 1.72, and 1.30-fold greater than those of reference drug colchicine. The second most effective compounds against the HCT116, HepG2, and MCF-7 cell lines were discovered to be compound 8f, with IC_{50} values of 4.83, 6.15, and 8.21 μM , respectively, which are around 1.54, 1.52, and 1.25-fold greater than the reference medication colchicine. Comparing compound 8d to the reference medication colchicine, it shows virtually identical efficacy against cancer cell lines under test. The investigated cell lines were resistant to the moderate activity of compounds 8a, 8b, and 8c. A crucial aspect of cancer chemotherapy's safety is its ability to specifically destroy



Scheme 1. Synthetic pathway of targeted compounds.

Table 1
Structure of target compounds.

Compound	R	Final structure
8a	-CH ₃	
8b	-CF ₃	
8c		
8d		
8e		
8f		

cancer cells while not impacting healthy cell proliferation. In this regard, the MTT test was used to analyze all the substances for potential cytotoxicity in normal Vero cell lines. The experiment results revealed that while none of the chemicals showed toxicity even at 50 μ M, they did not significantly impair the development of normal cells. Investigated the impact of substituent groups connected to the oxadiazole ring on the inhibitory action. When comparing the antiproliferative effects of compounds with methyl (8a) and trifluoromethyl (8b) groups, the results suggested that a substituted phenyl ring on oxadiazole ring would be advantageous. It's

Table 2
Cytotoxic activity of tested compounds 8a-f on cancer cell lines.

Compound	IC ₅₀ (μM) ^a		
	HCT116	HepG2	MCF-7
8a	21.86 ± 0.95	25.17 ± 1.03	28.43 ± 0.82
8b	13.08 ± 0.69	17.93 ± 0.81	19.27 ± 1.08
8c	8.57 ± 0.49	10.15 ± 0.73	12.71 ± 0.91
8d	7.55 ± 0.55	9.26 ± 0.91	10.18 ± 0.63
8e	3.19 ± 0.13	5.43 ± 0.21	7.89 ± 0.48
8f	4.83 ± 0.22	6.15 ± 0.31	8.21 ± 0.27
Colchicine	7.45 ± 0.31	9.36 ± 0.48	10.31 ± 0.75

interesting to note that compounds with trifluoromethyl (8e) and nitro (8f) groups on the phenyl ring connected to the oxadiazole exhibited a much higher level of cytotoxic activity than those with fluoro (8c) and chloro (8d) substituents.

3.3. Tubulin polymerization assay

The *in vitro* tubulin polymerization inhibitory activity of target compounds 8a-f was assessed to determine whether tubulin is the target of this class of chemicals. The microtubule polymerization inhibition experiment was turbidimetrically evaluated using a fluorescence plate reader. Colchicine was employed as a successful control. The investigated molecules IC₅₀ values were determined and recorded in Table 3. With IC₅₀ values of 7.95 and 9.81 nM, respectively compounds 8d and 8e showed the strongest tubulin assembly inhibition among the investigated compounds and outperformed the reference medication colchicine (IC₅₀ = 9.83 nM). The remaining molecules that underwent testing displayed some degree of inhibition, with IC₅₀ values ranging from 15.33 to 40.16 nM.

3.4. Molecular docking study

A key technique in the drug development toolkit is molecular docking, which forecasts the orientation, interactions, and docking scores of ligands in their intended binding sites. In order to better understand the effectiveness of the synthetic chemicals, we looked at how the oxadiazole derivatives interacted with the crystal structure of tubulin. Numerous cellular processes, such as mitosis, cell signaling, and organelle transport, depend heavily on microtubules. There are three primary places on tubulin where medications that target the microtubule can bind: the paclitaxel site, the vinca alkaloid site, and the colchicine binding site [28]. Microtubules have been acknowledged as one of the effective and efficacious pharmacological targets for the development of innovative anticancer medications due to their significant involvement in cell proliferation [29]. To interact with the target molecules, we selected the tubulin complex with colchicine (PDB ID: 4O2B). The ranking criteria utilized the expected docking score (kcal/mol). The compound was inserted into the tubulin's colchicine binding site to achieve molecular docking. When compared to the reference ligand colchicine, the selected pose of the new compounds exhibited the most similarity to the binding mode. Redocking of the lead compounds in the active site was performed to confirm docking methodology validation, which provided good results with an RMSD value 1.10 Å, showing that this molecular docking protocol is credible. Figs. 2 and 3 depict the molecular overlay of the best-scoring binding mode and their interactions with tubulin at the active site. Table 4 contains a list of the target compounds 8a-f docking interaction outcomes with the target protein. The compounds 8a-f had docking scores between -11.88 and -13.69 kcal/mol. The most potent compounds in this series, 8e and 8f, have docking scores that are higher than the reference medication colchicine (-13.69 kcal/mol) at -13.69 and -13.61, respectively. The free binding energies of compounds 8a, 8b, 8c, and 8d ranged from -11.88 to -12.83 kcal/mol, and they had lower docking scores than the reference medication colchicine. The X-ray crystallographic enzyme tubulin complex with colchicine revealed a significant hydrogen bond with Cys-797, as well as pi-pi, pi-alkyl, and hydrophobic interactions. According to the findings, compound 8e connected to the protein residues Cys-797 and Tyr-801 via two hydrogen bonds and Ile-821 and Val-843 via a π-alkyl interaction. With the protein residues Cys-797 and Tyr-801, compound 8f formed two hydrogen bonds with them. It also formed one π-π and π-alkyl link with Trp-817 and Val-845, respectively. Similarly, compounds 8b and 8c engaged in a π-π interaction with Tyr-801 whereas compounds 8a, 8b, 8c, and 8d created a hydrogen bond with Cys-797 (Figure S1-S4in supplementary file). The target compound's robust activity, as evidenced by its high docking score and docking pattern, is supported by its capacity to interact

Table 3
In vitro tubulin polymerization inhibition results.

Compound	IC ₅₀ (nM)
8a	40.16 ± 0.83
8b	28.39 ± 0.95
8c	18.41 ± 0.46
8d	15.33 ± 0.62
8e	7.95 ± 0.31
8f	9.81 ± 0.55
Colchicine	9.83 ± 0.65




Fig. 2. Docking poses of potent compounds 8e and 8f with the target tubulin-colchicine complex (PDB ID: 4O2B).




Fig. 3. 2D Interactions of potent compounds 8e and 8f with the target tubulin-colchicine complex (PDB ID: 4O2B).

with important amino acids in the target protein binding site. The results of the molecular docking studies and the biological tests were in accord, and compounds 8e and 8f showed a significant cytotoxic and tubulin inhibitory effect.

3.5. Drug likeness study

Traditionally, it takes a long time to manufacture interesting drugs and employ them since their pharmacokinetic features need to be investigated. A pharmaceutical company's research and development budget is significantly burdened as a result. As a result, Lipinski's rule of five may be used to pinpoint some of the crucial characteristics of substances that are theoretically thought of as drugs [30]. The drug-like properties of all the synthesized compounds 8a-f were estimated using the SwissADME online programme (Table 5). According to Lipinski's "rule of five", molecules need to have strong membrane permeability, $MW < 500$, $\log P < 5$, $HBD < 5$, and $HBA < 10$. The newly synthesized molecule 8e has violated one criterion, according to an analysis of the molecules, as its molecular weight is larger than 500. There were no infractions of these restrictions in the other parts of the facility, 8a-f. We also calculated the total polar surface area (TPSA), which is an important factor influencing the bioavailability of medications. As a result, substances with $TPSA > 140$ that are passively absorbed are thought to have a low oral bioavailability. According to the predictions in Table 5, each chemical has good $\log Kp$ values for the permeability of human skin. These findings suggest that the newly synthesized oxadiazole derivatives might be used as secure lead compounds.

Table 4
Docking scores and interactions of target compounds with protein.

Compound	Docking score (kcal mol ⁻¹)	Interacting residues			
		H-bond	Hydrophobic	π - π	π -alkyl
8a	-11.88	Cys-797	Gly-796, Leu-798, Leu-799, Tyr-801, Val-802, Arg-803, His-805, Ile-809, Ala-840, Val-843, Leu-844, Thr-847, Gln-849, His-850, Leu-907	NF	Val-845
8b	-12.09	Cys-797	Phe-795, Gly-796, Leu-798, Leu-799, Asp-800, Val-802, Glu-804, His-805, Tyr-813, Ala-840, Arg-841, Val-843, Leu-844, Val-845, Pro-848	Trp-817	Val-845
8c	-12.51	Cys-797	Phe-795, Gly-796, Leu-799, Tyr-801, Arg-803, Glu-804, His-805, Ile-809, Trp-817, Arg-841, Ile-821, Val-843, Pro-848, Lys-852, Leu-907	Tyr-801	Val-851
8d	-12.83	Cys-797	Phe-795, Gly-796, Leu-798, Leu-799, Asp-800, Val-802, Arg-803, Glu-804, His-805, Ile-809, Gln-820, Leu-844, Pro-848, His-850, Lys-852, Leu-907	NF	Ile-821, Val-843
8e	-13.69	Cys-797, Tyr-801	Leu-798, Leu-799, Asp-800, Val-802, Arg-803, Glu-804, His-805, Ile-809, Trp-817, Gln-820, Leu-844, Val-845, Pro-848, His-850, Val-851, Lys-852, Leu-907	NF	Ile-821, Val-843
8f	-13.61	Cys-797, Tyr-801	Phe-795, Leu-798, Leu-799, Asp-800, Val-802, Arg-803, Glu-804, His-805, Ile-809, Ile-821, Val-843, Thr-847, His-850, Lys-852, Val-851, Leu-907	Trp-817	Val-845

Table 5
Physicochemical properties of the title compounds.

Compound	Mol. Wt.	Rotatable bonds	HBA	HBD	logP	Molar Refractivity	log K _p (cm/s)	TPSA (Å ²)
8a	379.40	6	6	0	3.16	94.70	-5.54	80.96
8b	433.37	7	9	0	3.16	94.73	-5.50	80.96
8c	459.46	7	7	0	3.59	115.13	-5.06	80.96
8d	475.91	7	6	0	3.57	120.18	-4.79	80.96
8e	509.47	8	9	0	3.77	120.17	-4.81	80.96
8f	486.47	8	8	0	3.29	123.99	-5.42	123.99
Colchicine	399.44	6	6	1	3.28	109.36	-8.01	83.09
Lipinski rule	≤500	-	<10	<10	<5	40-130	-	-

4. Conclusion

In conclusion, a series of novel oxadiazole compounds 8a-f were developed and examined using spectroscopic methods. The *in vitro* tubulin inhibitory activity of the target compounds as well as their anticancer efficacy against three human cancer cell lines, including HCT116, HepG2 and MCF-7 as well as the normal Vero cell line, were assessed. The tubulin inhibition and substantial cytotoxicity were present in all of the new oxadiazole derivatives. Comparing them to the reference medication colchicine, compounds 8e and 8f from the synthesized group showed the most cytotoxic effect against the tested cancer cell lines. Compound 8e had the strongest tubulin polymerization inhibitory effect (IC₅₀ value of 7.95 nM) and the highest docking score (-13.69 kcal/mol). It also showed a strong cytotoxic impact with IC₅₀ values of 3.19, 5.43, and 7.89 μ M against the cancer cell lines HCT 116, HEPG-2, and MCF-7, respectively. Furthermore, molecular docking studies revealed that the potent compounds 8d, 8e, and 8f bind to the tubulin's colchicine-binding site with good affinity, and all of these compounds could function as a lead molecule for upcoming pharmaceuticals because of their *in silico* physicochemical properties. These findings imply that the most effective compounds, 8e and 8f, might be employed as prospective leads molecules for additional research in the creation of anticancer drugs.

Author contribution statement

Tarek A. Yousef: Performed the experiments; Wrote the paper. Abdulrahman G. Alhamzani, Mortaga M. Abou-Krishna: Performed the experiments. G. Kanthimathi, M. S. Raghu: Analyzed and interpreted the data. K. Yogesh Kumar: Contributed reagents, materials, analysis tools or data. M. K. Prashanth, Byong-Hun Jeon: Conceived and designed the experiments; Wrote the paper.

Funding statement

This work was supported by Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University through Research Group no. RG-21-09-72. Byong-Hun Jeon was supported by Korea Institute of Energy Technology Evaluation and Planning (KETEP) grants funded by the Ministry of Trade, Industry and Energy (MOTIE) of the South Korean Govt. (No.20206410100040).

1. Data availability statement

No data was used for the research described in the article.

Declaration of interest's statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at.

Acknowledgments

The authors immensely express their indebted gratitude to the Management of BNM Institute of Technology for providing lab facilities to carry out this work.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.heliyon.2023.e13460>.

References

- [1] Z. Su, Z. Yang, Y. Xu, Y. Chen, Q. Yu, Apoptosis, autophagy, necroptosis, and cancer metastasis, *Mol. Cancer* 14 (2015) 48.
- [2] M. Al-Anazi, M. Khairuddean, B.O. Al-Najjar, M. Murwih Alidmat, N.N.S.N. Mohamed Kamal, M. Muhamad, Synthesis, anticancer activity and docking studies of pyrazoline and pyrimidine derivatives as potential epidermal growth factor receptor (EGFR) inhibitors, *Arab. J. Chem.* 15 (2022), 103864.
- [3] A.M. Shawky, A.N. Abdalla, N.A. Ibrahim, M.A.S. Abourehab, A.M. Gouda, Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: design, synthesis, cytotoxicity, and MDR reversal activities, *Eur. J. Med. Chem.* 218 (2021), 113403.
- [4] L. Falzone, S. Salomone, M. Libra, Evolution of cancer pharmacological treatments at the turn of the third millennium, *Front. Pharmacol.* 9 (2018) 1300.
- [5] M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs, *Nat. Rev. Cancer* 4 (2004) 253–265.
- [6] A. Vicente-Blazquez, M. Gonzalez, R. Alvarez, S. del Mazo, M. Medarde, R. Pelaez, Antitubulin sulfonamides: the successful combination of an established drug class and a multifaceted target, *Med. Res. Rev.* 39 (2019) 775–830.
- [7] K. Haider, S. Rahaman, M.S. Yar, K. Ahmed, Tubulin inhibitors as novel anticancer agents: an overview on patents (2013–2018), *Expert Opin. Ther. Pat.* 29 (2019) 623–641.
- [8] R.O. Carlson, New tubulin targeting agents currently in clinical development, *Expert Opin. Invest. Drugs* 17 (2008) 707–722.
- [9] N. Shobeiri, M. Rashedi, F. Mosaffa, A. Zarghi, M. Ghandadi, A. Ghasemi, R. Ghodsi, Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors, *Eur. J. Med. Chem.* 114 (2016) 14–23.
- [10] S.D. Guggilapu, L. Guntuku, T.S. Reddy, A. Nagarsenkar, D.K. Sigalapalli, V.G. Naidu, S.K. Bhargava, N.B. Bathini, Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors, *Eur. J. Med. Chem.* 138 (2017) 83–95.
- [11] R.K. Bommera, S. Kethireddy, R.R. Govindapur, E. Laxminarayana, Synthesis, biological evaluation and docking studies of 1,2,4-oxadiazole linked 5-fluorouracil derivatives as anticancer agents, *BMC Chem.* 15 (2021) 30.
- [12] M.M. Alam, 1,3,4-Oxadiazole as a potential anti-cancer scaffold: a review, *Biointerface Res. Appl. Chem.* 12 (2022) 5727–5744.
- [13] S. Nayak, S.L. Gaonkar, E.A. Musad, A.M.A.L. Dawsar, 1,3,4-Oxadiazole-containing hybrids as potential anticancer agents: recent developments, mechanism of action and structure-activity relationships, *J. Saudi Chem. Soc.* 25 (2021), 101284.
- [14] J. Bostrom, A. Hogner, A. Llinas, E. Wellner, A.T. Plowright, Oxadiazoles in medicinal chemistry, *J. Med. Chem.* 55 (2012) 1817–1830.
- [15] C.E. Stecoza, G.M. Nitulescu, C. Draghici, M.T. Caproui, O.T. Oлару, M. Bostan, M. Mihaila, Synthesis and anticancer evaluation of new 1,3,4-oxadiazole derivatives, *Pharmaceuticals* 14 (2021) 438.
- [16] F. Naaz, F. Ahmad, B.A. Lone, Y.R. Pokharel, N.K. Fuloria, S. Fuloria, M. Ravichandran, L. Pattabhiraman, S. Shafi, M.S. Yar, Design and synthesis of newer 1,3,4-oxadiazole and 1,2,4-triazole based Toposentin analogues as anti-proliferative agents targeting tubulin, *Bioorg. Chem.* 95 (2020), 103519.
- [17] M.P. Tantak, M. Malik, L. Klingler, Z. Olson, A. Kumar, R. Sadana, D. Kumar, Indolyl- α -keto-1,3,4-oxadiazoles: synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization, *Bioorg. Med. Chem. Lett.* 37 (2021), 127842.
- [18] A.S. Kiselyov, M.N. Semenova, N.B. Chernyshova, A. Leitao, A.V. Samet, K.A. Kislyi, M.M. Raihstat, T. Oprea, H. Lemcke, M. Lantow, D.G. Weiss, N.N. Ikizalp, S. A. Kuznetsov, V.V. Semenov, Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays, *Eur. J. Med. Chem.* 45 (2010) 1683–1697.
- [19] O.O. Ajani, K.T. Iyaye, Recent advances on oxadiazole motifs: synthesis, reactions and biological activities, *Mediterr. J Chem.* 10 (2020) 418–452.
- [20] M.S. Raghu, C.B. Pradeep Kumar, M.K. Prashanth, K. Yogesh Kumar, B.S. Prathibha, G. Kanthimathi, S.A. Alissa, H.A. Alghulikhah, S.M. Osman, Novel 1,3,5-triazine-based pyrazole derivatives as potential antitumor agents and EGFR kinase inhibitors: synthesis, cytotoxicity, DNA binding, molecular docking and DFT studies, *New J. Chem.* 45 (2021) 13909–13924.
- [21] R. Ravvesha, A.M. Anusuya, A.V. Raghu, K. Yogesh Kumar, M.G. Dileep Kumar, S.B. Benaka Prasad, M.K. Prashanth, Synthesis and characterization of novel thiazole derivatives as potential anticancer agents: molecular docking and DFT studies, *Comput. Toxicol.* 21 (2022), 100202.
- [22] C.B.P. Kumar, M.S. Raghu, B.S. Prathibha, M.K. Prashanth, G. Kanthimathi, K.Y. Kumar, L. Parashuram, F.A. Alharthi, Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: molecular docking study, *Bioorg. Med. Chem. Lett.* 44 (2021), 128118.
- [23] M.S. Raghu, K. Yogesh Kumar, K. Veena, C.B. Pradeep Kumar, A.S. Almalki, G. Mani, F.A. Alasmary, M.K. Prashanth, Synthesis, characterization, antimicrobial and interaction studies of pteridines with human serum albumin: a combined multi-spectroscopic and computational study, *J. Mol. Struct.* 1250 (2022), 131857.
- [24] K. Veena, M.S. Raghu, K. Yogesh Kumar, K.A. Dahlous, A.A. Awadh Bahajaj, G. Mani, Byong-Hun Jeon, M.K. Prashanth, Development of penipanonid C-inspired 2-benzoyl-1-methyl-2, 3-dihydroquinazolin-4 (1H)-one derivatives as potential EGFR inhibitors: synthesis, anticancer evaluation and molecular docking study, *J. Mol. Struct.* 1258 (2022), 132674.
- [25] K. Veena, M.S. Raghu, K. Yogesh Kumar, CB Pradeep Kumar, Fahad A. Alharthi, M.K. Prashanth, Byong-Hun Jeon, Design and synthesis of novel benzimidazole linked thiazole derivatives as promising inhibitors of drug-resistant tuberculosis, *J. Mol. Struct.* 1269 (2022), 133822.
- [26] K. Yogesh Kumar, C.B. Pradeep Kumar, K.N.N. Prasad, B.H. Jeon, A. Alsalm, M.K. Prashanth, Microwave-assisted N-alkylation of amines with alcohols catalyzed by $MnCl_2$: anticancer, docking, and DFT studies, *Arch. Pharm.* 355 (2022), 2100443.
- [27] G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, *J. Comput. Chem.* 19 (1998) 1639–1662.

- [28] D. Bates, A. Eastman, Microtubule destabilising agents: far more than just antimitotic anticancer drugs, *Br. J. Clin. Pharmacol.* 83 (2017) 255–268.
- [29] E. Mukhtar, V.M. Adhami, H. Mukhtar, Targeting microtubules by natural agents for cancer therapy, *Mol. Cancer Therapeut.* 13 (2014) 275–284.
- [30] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv. Drug Deliv. Rev.* 46 (2001) 3–26.